Sellas Life Sciences is trading 5.5% down at $14.38, with no fresh company announcement identified to explain the August 28, 2026 decline.
- Recent coverage points to investor focus on the event-dependent REGAL trial readout.
- The latest official update said final analysis begins after the 80th event.
- That readout remains an unresolved catalyst, not a confirmed cause of today’s drop.